Disclosed are nonlimiting embodiments comprising novel methods for treating underactive bladder in a subject, including administering an effective amount of a pharmaceutical composition comprising an Ml -selective muscarinic agonist to the subject. In some embodiments, the Ml -selective muscarinic agonist is cevimeline.